Изготовлены и исследованы планарные алмазные «солнечно-слепые» фотоприемники УФ-диапазона. Приведено теоретическое обоснование принципов работы и экспериментальные параметры фотоприемников в фоторезистивном и фотодиодном режимах

Ananja Middel (746837)

Andy Hoepelman (746839)

Annemarie Wensing (594593)

Clemens Richter (746833)

Ellen Veel (746832)

Frank Kroon (746836)

Jan Prins (746834)

Jan Willem Mulder (746835)

Jori Symons (68630)

Jose Borghans (746838)

Julia Drylewicz (567694)

Kees Brinkman (175845)

Kiki Tesselaar (651248)

Maaike Krikke (746831)

Monique Nijhuis (89548)

Robin Soetekouw (175854)

Sigrid Otto (651247)

Steven Van lelyveld (746820)

Технология и конструирование в электронной аппаратуре

PubMed

File: Ki67+ CD4 and CD8 T cells.
This SPSS file contains the percentage of Ki67+ CD4 and CD8 T cells at various time points during the MIRS trial.
Please see the 'variable view' of the SPSS file and the 'methods' section of the paper for more information.
We have used SAS software for our analyses.</p

FigShare

Maraviroc intensification of cART in patients with suboptimal immunological recovery: a 48-week, placebo-controlled randomized trial

<div>ObjectiveThe immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled trial to determine the effect of maraviroc intensification on CD4+ T-cell counts and immune activation in these patients.DesignDouble-blind, placebo-controlled, randomized trial.MethodsMajor inclusion criteria were 1. CD4+ T-cell count <350 cells/μL while at least two years on cART or CD4+ T-cell count <200 cells/μL while at least one year on cART, and 2. viral suppression for at least the previous 6 months. HIV-infected patients were randomized to add maraviroc (41 patients) or placebo (44 patients) to their cART regimen for 48 weeks. Changes in CD4+ T-cell counts (primary endpoint) and other immunological parameters were modeled using linear mixed effects models.ResultsNo significant differences for the modelled increase in CD4+ T-cell count (placebo 15.3 CD4+ T cells/μL (95% confidence interval (CI) [1.0, 29.5] versus maraviroc arm 22.9 CD4+ T cells/μL (95% CI [7.4, 38.5] p = 0.51) or alterations in the expression of markers for T-cell activation, proliferation and microbial translocation were found between the arms. However, maraviroc intensification did increase the percentage of CCR5 expressing CD4+ and CD8+ T-cells, and the plasma levels of the CCR5 ligand MIP-1β. In contrast, the percentage of ex-vivo apoptotic CD8+ and CD4+ T-cells decreased in the maraviroc arm.ConclusionsMaraviroc intensification of cART did not increase CD4+ T-cell restoration or decrease immune activation as compared to placebo. However, ex-vivo T-cell apoptosis was decreased in the maraviroc arm.Trial RegistrationClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT00875368" target="_blank">NCT00875368</a></div

Steven F. L. van Lelyveld (774981)

Ellen M. Veel (774982)

Sigrid A. Otto (774983)

Jan M. Prins (175858)

Annemarie M. J. Wensing (105565)

José A. M. Borghans (34539)

Andy I. M. Hoepelman (214476)

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

Алтухов, А.А.

Митягин, А.Ю.

Горохов, Е.В.

Фещенко, В.С.

Талипов, Н.Х.

Наукова електронна бібліотека періодичних видань НАН України (Vernadsky National Library of Ukraine)

Алмазные фотоприемники ультрафиолетового диапазона

File: Annexin-V+ CD4+ and CD8+ T cells.
This SPSS file contains the percentage of Annexin-V+ CD4+ and CD8+ T cells at various time points during the MIRS trial.
Please see the 'variable view' of the SPSS file and the 'methods' section of the paper for more information.
We have used SAS software for our analyses.</p

Objective The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled trial to determine the effect of maraviroc intensification on CD4+ T-cell counts and immune activation in these patients. Design Double-blind, placebo-controlled, randomized trial. Methods Major inclusion criteria were 1. CD4+ T-cell count + T-cell count + T-cell counts (primary endpoint) and other immunological parameters were modeled using linear mixed effects models. Results No significant differences for the modelled increase in CD4+ T-cell count (placebo 15.3 CD4+ T cells/μL (95% confidence interval (CI) [1.0, 29.5] versus maraviroc arm 22.9 CD4+ T cells/μL (95% CI [7.4, 38.5] p = 0.51) or alterations in the expression of markers for T-cell activation, proliferation and microbial translocation were found between the arms. However, maraviroc intensification did increase the percentage of CCR5 expressing CD4+ and CD8+ T-cells, and the plasma levels of the CCR5 ligand MIP-1β. In contrast, the percentage of exvivo apoptotic CD8+ and CD4+ T-cells decreased in the maraviroc arm. Conclusions Maraviroc intensification of cART did not increase CD4+ T-cell restoration or decrease immune activation as compared to placebo. However, ex-vivo T-cell apoptosis was decreased in the maraviroc arm

van Lelyveld, Steven F. L.

Drylewicz, Julia

Krikke, Maaike

Veel, Ellen M.

Otto, Sigrid A.

Richter, Clemens

Soetekouw, Robin

Prins, Jan M.

Brinkman, Kees

Mulder, Jan Willem

Kroon, Frank

Middel, Ananja

Symons, Jori

Wensing, Annemarie M J

Nijhuis, Monique

Borghans, José A M

Tesselaar, Kiki

Hoepelman, Andy I M

NARCIS 

Maraviroc intensification of cART in patients with suboptimal immunological recovery : A 48-week, placebo-controlled randomized trial

Steven F. L. van Lelyveld

Julia Drylewicz

Maaike Krikke

Ellen M. Veel

Sigrid A. Otto

Clemens Richter

Robin Soetekouw

Jan M. Prins

Kees Brinkman

Jan Willem Mulder

Frank Kroon

Ananja Middel

Jori Symons

Annemarie M. J. Wensing

Monique Nijhuis

José A. M. Borghans

Kiki Tesselaar

Andy I. M. Hoepelman

null null

Crossref

PLoS ONE

File: Baseline immunological parameters.
This SPSS file contains the baseline immunological parameters of the participants of the MIRS trial.
Please see the 'variable view' of the SPSS file and the 'methods' section of the paper for more information.
We have used SAS software for our analyses.</p

File: CD4 and CD8 subsets.
This SPSS file contains the absolute number of CD4 and CD8 T cell subsets, as well as the percentage of CD31+ in CD4  naive T cells, at various time points during the MIRS trial.
Please see the 'variable view' of the SPSS file and the 'methods' section of the paper for more information.
We have used SAS software for our analyses.
 </p

File: General/clinical baseline parameters.
This SPSS file contains the general/clinical baseline parameters of the participants of the MIRS trial.
Please see the 'variable view' of the SPSS file and the 'methods' section of the paper for more information.
We have used SAS software for our analyses.</p

https://figshare.com/articles/_Maraviroc_Intensification_of_cART_in_Patients_with_Suboptimal_Immunological_Recovery_A_48_Week_Placebo_Controlled_Randomized_Trial_/1493496

Алмазные фотоприемники ультрафиолетового диапазона

Abstract

Similar works

Full text

Available Versions

FigShare

FigShare

Наукова електронна бібліотека періодичних видань НАН України (Vernadsky National Library of Ukraine)

FigShare

NARCIS

Crossref

FigShare

FigShare

FigShare